Resistance to glucocorticoids (GCs) is a major clinical problem in the treatment of acute lymphoblastic leukemia (ALL), but the underlying mechanisms are not well understood.
Introduction
Acute Lymphoblastic Leukemia (ALL) is the most common type of cancer in children.
Although cure rates are exceeding 80%, therapy resistance and associated disease relapse remain a significant clinical problem. Pediatric ALL is a genetically heterogeneous disease characterized by chromosomal abnormalities including translocations, aneuploidies, and deletions. Molecular analysis of the most common chromosomal alterations in ALL has allowed classification into different subtypes that are associated with distinct clinical outcome. In addition to these chromosomal abnormalities, prognosis is determined by blast count at diagnosis, lineage (B or T cell) and the initial response to therapy 1 . Despite these advances in the molecular pathology of pediatric ALL, little is known about the mechanisms that contribute to relapse or therapy resistance in the patient.
Synthetic glucocorticoids (GCs) are essential drugs in the treatment of pediatric ALL, as they effectively induce apoptosis in leukemic blasts. GCs exert their effects by binding to the glucocorticoid receptor (GR), a ligand-activated receptor and member of the nuclear receptor family. Activation of the GR by GCs leads to recruitment of GR to large transcription regulatory complexes that modulate expression of GC response genes, which leads to the induction of apoptosis in lymphoblasts. Resistance to GCs is a major clinical problem predictive of poor therapy outcome 2 . In most in vitro models, resistance to GCs appears to occur at the level of the receptor, either by mutations in the GR or by the inability of cells to upregulate the GR in response to GC exposure, a phenomenon known as GR autoinduction 3 . However, mutations in the GR are rarely seen in (relapsed) ALL 4 and it remains unclear to what extent differences in GR expression affect therapy response in the patient 5, 6 .
Through genome-wide profiling using SNP-based array comparative genomic hybridization (CGH), we and others recently identified a number of novel submicroscopic For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From lesions that may either contribute to the development of acute lymphoblastic leukemia (ALL) or determine the response to therapy 7, 8 . Focal micro-deletions, often smaller than 0.5 Mb and containing single genes, were identified with a relatively high frequency. The genes most frequently affected by these microdeletions are either implicated in B-cell differentiation, cell survival or cell cycle progression 7, 8 . A novel recurrent single-gene lesion observed in pediatric pre-B ALL involves the B-cell translocation 1 gene (BTG1) [7] [8] [9] . This gene was originally identified as translocation partner of the c-MYC gene in a case of B-cell chronic lymphocytic leukemia and belongs to a family of anti-proliferative genes that also includes BTG2, BTG3, TOB and TOB2 10, 11 . Proteins encoded by members of this gene family have been implicated in the induction of growth arrest or apoptosis in a variety of cell systems 12 .
Overexpression of BTG1 was found to block proliferation during normal erythroid differentiation 13 and to induce growth arrest in a B-cell lymphoma model 14 . The BTG1 protein has no proven intrinsic enzymatic activity, but the presence of several protein interaction domains suggests that BTG1 either functions as an adaptor molecule or as a cofactor involved in transcriptional regulation. For instance, BTG1 was identified as coactivator of the homeobox transcription factor HoxB9 15 and the transcriptional regulator CAF1 16 . Moreover, BTG1 was shown to stimulate the activity of several myogenic transcription factors as well as nuclear receptors during muscle cell differentiation 17 .
BTG1 interacts with and regulates the activity of the arginine methyltransferase PRMT1 11, 18 . Members of this enzyme family, including PRMT1, are considered global regulators of gene expression that act as transcriptional coregulators by arginine methylation of histone tails and critical transcriptional regulators 19 . PRMT1 was shown to act as a histone H4 Arg-3-specific methyltransferase involved in transcriptional activation of several nuclear receptors [20] [21] [22] . However a role for either BTG1 or PRMT1 in GR activation has not been investigated. In the present study we identify BTG1 as a critical determinant of glucocorticoid 
Materials and methods

Collection Leukemia samples and maintenance ALL cell lines
Lymphoblast samples of patients treated according to the current clinical protocol were obtained with informed consent in accordance with the Declaration of Helsinki and with the approval and supervision of the Medical Ethics Committee of the Radboud University Nijmegen Medical Centre. ALL-derived cell lines RS4;11, REH and SUP-B15 were purchased from ATCC (Manassas, VA, USA). Primary lymphoblasts, RS4;11 and REH cells were maintained in RPMI 1640 with L-Glutamine (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) (Greiner Bio-One) and 100 units/ml Penicillin/Streptomycin (Invitrogen), while SUP-B15 cells were maintained in IMDM with L-Glutamine, 20% FBS and 100 units/ml Penicillin/Streptomycin.
Multiplex Ligation-dependent Probe Amplification (MLPA) and sequence analyses
Nine MLPA probes covering the BTG1 gene (Table S1/ Figure S1A) were combined in one MLPA assay along with four standard control probes in three different genes, i.e., VIRP2, MRPL41, and KIAA0056 according to guidelines of MRC-Holland (Amsterdam, The Netherlands). Amplification products were quantified and identified by capillary electrophoresis on an ABI 3730 genetic analyzer (Applied Biosystems, Forster City, CA).
Normalization of the data was performed by dividing the peak area of each probe by the average peak area of the control probes. This normalized peak pattern was divided by the average peak pattern of all the samples in the same experiment. The resulting values were approximately 1.0 for every wild-type peak, 0.5 for heterozygous deletions, and 1.5 for heterozygous duplications.
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Lentiviral knockdown in ALL cell lines
shRNAs were introduced using the BLOCK-iT U6 RNAi Entry Vector in combination with the pLenti6/BLOCK-iT DEST vector according to the manufacturer's protocol (Invitrogen).
Two shRNA sequences were directed against BTG1 mRNA (NM_001731.1): 5'gctctctgtacatttgctagc-3' (shRNA1), 5'-gctgctggcagaacattataa-3' (shRNA2). A non-functional shRNA (5'-gctacaagagaaaccaaatct-3'), originally designed to target myosin X, which is not expressed in lymphocytes, was used as a negative control. The individual vectors were cotransfected with packaging vectors into the 293FT cells according to manufacturer's instructions. Virus was produced in DMEM medium containing Glutamax (Invitrogen) supplemented with 10% FBS and 100 units/ml Penicillin/Streptomycin and collected from tissue culture supernatant 48 hours after transfection. Tissue culture plates were coated with Retronectin (Takara, Shiga, Japan) and virus supernatant was cocultured with ALL cell lines for 8 hours. Transduced cells were selected with 4 µg/ml blasticidin (Invitrogen).
Retroviral transduction and Western blot analysis
A BTG1 expression construct was generated by PCR. (forward primer: 5'gcgaattcgaccatggcttacccatacgatgttccagattacgctcatcccttctacacccggg-3' (HA tag in bold) ; reverse: 5'-gcctcgagttaacctgatacagtcatcatattg-3'), cloned into pLZRS-Neo and verified by sequencing. pLZRS-HA-BTG1 and pLib-T7-MSC2-IRESpuro-hGR (obtained from Prof. dr. R. Kofler, Innsbruck, Austria) were transfected into Phoenix amphotropic producer cells to generate retrovirus-containing supernatants. Cells were transduced in retronectin-coated tissue culture dishes and transduced cells were selected using 400 µg/ml G418 (Invitrogen) and 1 μg/ml puromycin. Antibodies directed against the glucocorticoid receptor (GR) (Santa Cruz Biotechnology, Santa Cruz, CA), α -tubulin (Sigma, Saint Louis, MO) and the HA epitope, clone 3F10 (Roche, Basel, Switzerland) were used in immunoblot assays using standard procedures.
Cytotoxicity assays
Cell viability was determined using the CellTiter 96® Aqueous One Solution Cell
Proliferation Assay (MTS) (Promega, Madison, WI). 1·10 5 cells were seeded in a 96-well culture plate and treated with increasing amounts of prednisolone (5·10 -3 to 5·10 3 µg/ml) Table   S2 .
Chromatin immunoprecipitation (ChIP) assays
Chromatin immunoprecipitations were performed as described elsewhere 23 
Luciferase reporter assays
The mouse mammary tumor virus promoter cloned upstream of the luciferase gene (MMTV-Luc) contains multiple GC-responsive elements (GREs), located between positions -202 and -79 upstream of the RNA start site, and was originally described by Hollenberg and Evans 24 .
293FT cells were seeded in 24-well plates (2·10 5 cells/well) . 6 hrs later, each well was transfected with 60 ng MMTV-Luc, 20 ng pCMV-HA-GR, 2 ng pRL-CMV (Promega) and
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From (Polysciences Inc., Warrington, PA). The DNA amount was supplemented with pcDNA plasmid to a total of 300 ng. The next day, prednisolone (3.6 μg/ml) or medium control was added to the wells and 16 hrs later cells were harvested and analyzed with a Dual-Luciferase Reporter Assay according to the supplier's instructions (Promega). Firefly luciferase values were normalized with renilla luciferase values, which served as an internal control.
Results
BTG1 copy number loss occurs frequently in pediatric precursor-B ALL
By high resolution genomic profiling of childhood ALL, we and others recently identified a recurrent microdeletion on the q-arm of chromosome 12 affecting the BTG1 locus in about 10% of precursor-B (pre-B) ALL cases ( Figure 1) [7] [8] [9] . In our study, copy-number losses of the BTG1 gene were found in 4 out of 33 cases examined. MLPA was used to confirm the presence of these micro-deletions ( Figure S1 ). As these BTG1 micro-lesions appeared to be mono-allelic, we performed exon sequencing to determine whether loss of function mutations in BTG1 could be observed in the other allele. Sequencing of the BTG1 gene was also performed in the remaining 29 cases to reveal the potential presence of smaller lesions or point mutations. However, in none of the cases showing a single-copy loss of BTG1 or in the other leukemia samples, additional mutations in BTG1 were found. The reported role of BTG1 as a regulator of differentiation, proliferation and cell survival 12 , suggest that BTG1 haploinsufficiency contributes to ALL development, preferentially through focal microdeletions. However, it remains to be established how BTG1 contributes to ALL development.
shRNA-mediated knockdown of BTG1 leads to GC resistance
BTG1 expression and function have been linked to the inhibition of cell growth and the induction of apoptosis in a variety of model systems 12 . Moreover, with one exception 25 , a number of studies have identified BTG1 as one of many genes upregulated in clinical isolates of ALL cells in response to synthetic GCs [26] [27] [28] . Similarly, we detected a 3-fold induction of BTG1 mRNA expression after exposure of either primary pre-B ALL cells, primary T-ALL cells or the pre-B ALL cell line RS4;11 to 1 mg/ml prednisolone for 8 hours (Figure 2A ).
Next, we determined to what extent BTG1 expression could be involved in the induction of GC-induced cell death. Using a lentiviral vector we expressed shRNAs targeting different areas of the BTG1 gene in RS4;11 pre-B ALL cells. With either of these shRNA constructs, BTG1 mRNA expression was reduced to less than 10% in comparison to cells transduced to express an irrelevant shRNA control ( Figure 2B ). Prednisolone treatment had only a minor effect on BTG1 levels, which remained low in BTG1 knockdown cells ( Figure 2B ).
The BTG1 knockdown cells showed a marked increase in growth rate as compared to shRNA control cells ( Figure 2C) , consistent with the observation that over-expression of BTG1 leads to a cessation of growth in other cell types 12 . Subsequently, a role for BTG1 in GC-induced apoptosis was examined by exposing control shRNA cells and BTG1 knockdown cells to increasing concentrations of prednisolone and assessing in vitro toxicity after three days of exposure using an MTS cell viability assay. Whereas vector control-transfected RS4;11 cells were highly sensitive to prednisolone exposure, with a 50% inhibitory concentration (IC 50 ) of 2.1·10 -2 µg/ml prednisolone at 72 hours, BTG1 knockdown cells had become largely refractory (IC 50 of 1.6·10 3 and 0.6·10 3 µg/ml for shRNA1 and shRNA2, respectively) to the cytotoxic effects of this drug ( Figure 2D ). During these 3 days of exposure to prednisolone BTG1 mRNA levels continued to increase in the control cells, while in the BTG1 knockdown cells the expression level remained low ( Figure S3A ). Similar to prednisolone, BTG1 knockdown cells also acquired resistance to the synthetic GC dexamethasone (IC 50 of 2.8·10 -4 , 2.3·10 2 and 1.9·10 2 µg/ml for control shRNA, shRNA1 and shRNA2, respectively) ( Figure   2E ). The protective effect of BTG1 knockdown on GC-induced cytotoxicity was confirmed using a flow cytometry-based apoptosis assay which measures exposure of Annexin-V and 7-AAD ( Figure S4 A-B ). These results demonstrate that loss of BTG1 expression is sufficient to induce GC resistance in vitro.
Loss of BTG1 expression effectively interferes with GR autoinduction and GC-induced gene expression
Having identified BTG1 as a critical determinant of GC-induced apoptosis, microarray expression analysis was used to compare GC-regulated transcript levels in RS4;11 control shRNA cells versus BTG1 knockdown cells. In the (GC-sensitive) RS4;11 control shRNA cells, we found that 951 genes were up-or down-regulated at least 2-fold after exposure to prednisolone ( Figure 3A ; Table S3 ). In contrast, in the BTG1 knockdown cells only 38 genes were differentially expressed in response to prednisolone ( Figure 3A ; Table S4 ). Of the top 200 ranked genes most strongly up-or down-regulated by prednisolone in control cells, the vast majority had become unresponsive to prednisolone in the BTG1 knockdown cells ( Figure   3B ; Table S3 ). Expression of three representative genes induced by GC exposure was confirmed by quantitative RT-PCR (qPCR) ( Figure 3C ). Notably, one of the genes strongly affected by BTG1 knockdown was the NR3C1 gene, which encodes the GC receptor (GR).
Expression of the GR was reduced more than 10-fold in the BTG1 knockdown cells relative to the RS4;11 control cells, as determined by qPCR ( Figure 3C ) and confirmed at the protein level by Western blotting ( Figure 3D ). These findings suggested that the inability of the BTG1 knockdown cells to respond to GCs could be due to severely reduced expression of the GR. In order to address if and how BTG1 would also affect expression of other GR-regulated genes, we complemented expression of the GR in the BTG1 knockdown cells by retroviral transduction of a GR transgene. GR expression levels obtained in these cells were than those in the control RS4;11 cells, as determined by Western blotting (Figure 3E ).
Even though GR expression was restored to endogenous levels in these cells, expression of GR-target genes in response to GCs could not be induced ( Figure S5 ), while no reversal of prednisolone resistance was seen ( Figure 3F ). These results demonstrate that GR expression per se is not sufficient to restore therapy responses, but requires the presence of For personal use only. on September 14, 2017. by guest www.bloodjournal.org From additional regulatory protein complexes. We similarly tried to restore expression of BTG1 in the shRNA1 knockdown cells, by retroviral transduction of an HA-BTG1 transgene (resistant to shRNA1). However, despite multiple attempts, we observed that enforced expression of HA-BTG1 in these cells was not tolerated.
BTG1 and GR synergize to reverse therapy responses in GC resistant REH pre-B ALL cells
To further define a role for BTG1 in controlling GC responsiveness, we made use of the GC resistant REH pre-B ALL cell line, which carries a single copy deletion of the BTG1 gene 29 .
Expression of the BTG1 mRNA could still be detected in these cells, albeit at a reduced level in comparison to RS4;11 cells ( Figure S6A ). In contrast, expression of the GR was almost undetectable in REH cells ( Figure S6B ), suggesting that also in these cells GC resistance may be due to lack of GR expression. To determine whether BTG1 haploinsufficiency in REH cells was directly linked to reduced GR mRNA levels, we complemented BTG1 expression by retroviral transduction of an HA-BTG1 transgene. In contrast to RS4;11 cells, expression of the HA-BTG1 transgene was readily detected in these cells ( Figure 4A ). Indeed, expression of (HA-tagged) BTG1 resulted in a marked upregulation of the GR mRNA, as determined by qPCR, particularly after exposure to prednisolone ( Figure 4B ). This phenomenon of GCinduced GR expression (GR autoinduction) is considered to contribute to the apoptosisinducing effects of GCs in leukemic blasts 30, 5 . In spite of increased GR autoinduction, expression of GR mRNA in the HA-BTG1 expressing REH cells still remained about 20 fold lower in comparison to the (GC sensitive) RS4;11 cells ( Figure S6C ). As a consequence, we were not able to detect the GR protein in these cells ( Figure 4A , results not shown). In agreement with these observations, only a partial reversal of GC resistance was observed, IC 50 value was reduced from 4.8 µg/ml in control cells to 2.8·10 -1 µg/ml in HA-BTG1 cells ( Figure  4C ). Similarly, raising GR expression levels by retroviral transduction of a GR transgene, was not sufficient to fully restore GC responses in the REH cells (IC 50 was reduced to 2.7·10 -1 µg/ml). However, when expression of HA-BTG1 and the GR were combined, a further 10fold increase in sensitivity to GCs was observed (IC 50 reduced to 3.0·10 -2 µg/ml) ( Figure 4C ), consistent with a role for BTG1 as a limiting cofactor in GR mediated gene regulation. In REH cells expressing HA-BTG1, this recombinant protein migrated as a single band of about 20 kDa. When expression of HA-BTG1 was combined with that of the GR, several discrete products representing HA-BTG1 were observed ( Figure 4A ), suggesting that under these conditions the BTG1 protein is subject to modification. The nature of this modification is currently under investigation.
To further explore a functional interaction between BTG1 and the GR, we analyzed expression of the GR-target genes TSC22D3/GILZ, and ZFP36L2/TIS11D, both of which have been linked to the antiproliferative effects of GCs in leukemic cells 26, 31 . In spite of the low GR expression in parental REH cells, a moderate induction of these genes was observed in response to prednisolone, which was further enhanced in the presence of the GR transgene ( Figure 4D ). Expression of HA-BTG1 only slightly increased GC-induced expression of TSC22D3/GILZ and ZFP36L2/TIS11D, however, combined expression of HA-BTG1 and the GR resulted in a significantly larger induction ( Figure 4D ). Together, these results strongly suggest that BTG1 and the GR synergize in the induction of GC-mediated gene expression and -apoptosis.
PRMT1 is recruited to GC responsive promoter elements
Several studies have demonstrated that BTG1 associates with and regulates the activity of PRMT1 18, 11 . Moreover, this arginine methyltransferase was shown to regulate transcription For personal use only. on September 14, 2017. by guest www.bloodjournal.org From mediated by a number of nuclear receptors, but a functional interaction between PRMT1 and the GR has not been established. Therefore, we examined by chromatin immunoprecipitation (ChIP) analysis whether BTG1, in complex with PRMT1, may control GR autoinduction. To this end, two independent PRMT1 antibodies were tested ( Figure S2 ). By doing so, a specific association between PRMT1 and the promoter regions of BTG1 and NR3C1 (GR) could be observed in response to GC exposure ( Figures 5A and S2) . These results establish PRMT1 as a novel GR coactivator. Importantly, this association was no longer present in the BTG1 knockdown cells ( Figure 5A ). As the loss of BTG1 expression in the knockdown cells is accompanied by a loss of GR expression, the lack of association between PRMT1 and these promoters could either be the result of reduced BTG1 expression, reduced GR expression, or a combination of the two.
BTG1 directly affects GR-mediated gene expression
In order to more directly implicate BTG1 in GR-mediated transcriptional regulation, we studied the effects of BTG1 on a MMTV-LUC reporter plasmid by transient transfection of 293FT cells. This GC responsive reporter plasmid, which contains the mouse mammary tumor (MMTV) promoter cloned upstream of the luciferase gene, harbors multiple GCresponsive elements (GREs) 24 . When this reporter was transfected in combination with low amounts of recombinant GR, we observed a robust (15 fold) activation of this promoter in response to prednisolone ( Figure 5B ) . Importantly, titration of increasing amounts of HA-BTG1 resulted in a -dose-dependent-increase in GR-induced transcriptional activation ( Figure 5B ). Based on these findings we propose that BTG1, possibly in association with the arginine methyltransferase PRMT1, promotes GR-mediated gene expression, while loss of BTG1 function contributes to GC resistance. This type of therapy resistance appears to For personal use only. on September 14, 2017. by guest www.bloodjournal.org From involve both defective GR autoregulation as well as reduced activation of GR target genes ( Figure 5C ).
Discussion
Despite the fact that GCs are essential drugs in the treatment of ALL and other lymphoid malignancies, the molecular mechanisms that lead to GC resistance in the patient remain unclear 2, 5 . It is evident, mostly from in vitro studies, that GC resistance can occur at the level of the GR, either by loss-of-function mutations in the GR [32] [33] [34] or by defective GR autoinduction 32 . However, acquired somatic mutations in the GR are rarely found in the patient and not related to GC resistance in vivo 35 . Moreover, in a recent study comparing GC resistant with GC sensitive ALL, no correlation between GR expression in patient samples and therapy response was seen 6 . These studies indicate that GR expression alone does not accurately predict therapy response but rather that GC sensitivity is highly dependent on cellular context such as the metabolic state of the cell 36 or the presence of specific genetic changes.
In this study we identify BTG1, a gene recurrently deleted in pre-B ALL, as a novel determinant of GC-induced apoptosis that acts by regulating GR-mediated gene expression.
Reduced expression of BTG1, either induced by shRNA mediated knockdown or by (single copy) deletion of the BTG1 gene, as observed in the REH cells, renders pre-B ALL cells refractory to the apoptosis inducing effects of GCs. This acquired GC resistance appears to be, at least in part, due to defective GR autoinduction. In RS4;11 cells, shRNA mediated knockdown of BTG1 leads to a more than 10-fold reduction in GR expression while restoration of BTG1 expression in BTG1 haploinsufficient REH cells promotes GR autoinduction. However, the effects of BTG1 on GR-mediated gene expression and associated therapy responses cannot be explained simply by increased GR expression levels. Restoring GR expression in RS4;11 BTG1 knockdown cells could not restore therapy responses in these in the REH cells was not sufficient to fully restore therapy response. Apparently, GR expression levels need to exceed a certain threshold before proper activation by BTG1 can take place. As BTG1 expression also increases in response to GC stimulation and GR autoinduction is dependent on BTG1, we conclude that BTG1 and the GR are part of a potent feed-forward autoregulatory loop that enhances the apoptosis inducing effects of GCs in ALL cells.
Similar to other nuclear receptors, GR-mediated transcription involves the sequential recruitment of transcriptional coregulators into multiprotein complexes. Components of these complexes include acetyl-and methyl transferases that modify transcription factors present in the complex and bring about specific combinations of histone modifications at these promoter sites 37, 38 . In this context, the arginine methyl transferase PRMT1 has been identified as a coactivator of the nuclear receptors HNF4 39, 20 , ER 40 and FXR 21 . Activation of the nuclear receptor HNF4α by PRMT1 involves a two-step process. Initially, PRMT1 methylates the receptor, thereby facilitating binding to the target promoter element, after which PRMT1 can bind to the receptor complex and locally methylate histone tails to further enhance transcription 20 . Hence, PRMT1 functions as a global regulator of gene expression and it was shown that disruption of normal PRMT1 function can contribute to leukemia formation 41 . As BTG1 was found to interact with PRMT1 42 , we postulated that the effects of BTG1 knockdown on GR-mediated gene expression might be due to a failure to recruit PRMT1 to For personal use only. on September 14, 2017. by guest www.bloodjournal.org From GC-responsive promoter elements. Consistent with such a model, ChIP assays using PRMT1 antibodies revealed that upon GC-exposure PRMT1 associates with the promoter regions of both BTG1 and the GR (NR3C1) in a BTG1-dependent manner. As ChIP grade antibodies for BTG1 are not available, we could not establish a direct association of BTG1 with these promoter elements by this method. Instead, luciferase reporter assays using the GCresponsive MMTV promoter were used to demonstrate that expression of recombinant HA-BTG1 enhances prednisolone-induced activation of this promoter in a dose-dependent manner. Since BTG1 and PRMT1 appear to cooperate in GC-mediated gene expression, shRNA mediated knockdown of PRMT1 was expected to similarly affect GC responsiveness.
Lentiviral knockdown of PRMT1 in RS4;11 cells, however, induced massive cell death within days after transduction (results not shown), which likely reflects other important nonredundant functions of PRMT1. The latter may be explained from the fact that PRMT1 is responsible for approximately 80% of all arginine methylation activity within the cell 43 .
Although our leukemia cell models provide valuable insights into how BTG1 and GR synergize in the control of GR-mediated gene expression, these results cannot be directly be translated to the clinical situation. For instance, a near complete loss of GR expression, as found in the REH cells, is not observed in primary ALL. Hence, it remains to be established to what extent BTG1 copy number losses contribute to therapy resistance in the patient.
Assessment of our small patient cohort (33 cases) revealed that a single copy loss of BTG1 at the time of diagnosis was not necessarily associated with a poor therapy response. In fact, in none of the patients a poor therapy response to initial GC therapy was observed. We therefore suspect that the effect of BTG1 copy number loss on GC responsiveness is highly dependent on the genetic and cellular context in which the lesion occurs. For instance BTG2, which shows overlapping expression patterns and functions with BTG1 14 , may compensate for the effects of BTG1 copy number loss. Consistent with such a compensatory role, GC sensitive For personal use only. on September 14, 2017. by guest www.bloodjournal.org From SUP-B15 pre-B ALL cells, which exhibit a BTG1 copy number loss, showed high expression of BTG2, particularly after stimulation with prednisolone, whereas in GC resistant REH cells, which also lack one copy of the BTG1 gene, expression of BTG2 was undetectable ( Figure   S6D ). A first clue that deletions in BTG1 may influence therapy outcome was recently provided by Mullighan and colleagues 44 . They showed, that (therapy induced) selection of malignant subclones, often already present at the time of diagnosis, may result in a therapyresistant relapse. In one of the cases examined, a BTG1 lesion not present at diagnosis, appeared in the relapse 44 . In addition, four other relapse samples were found to contain single copy deletions of the NR3C1 gene, which were not present at diagnosis. These results suggest that the GC therapy may have contributed to the selective outgrowth of these clones.
In the present study we show that loss of BTG1 expression, either induced by deletion or by shRNA mediated knockdown, is sufficient to induce GC resistance in the defined context of two model cell lines. It will be important to determine to what extent BTG1 or other members of the BTG/TOB family modulate GC-induced therapy responses in the patient. As GC-based therapies are used in a variety of medical conditions, a detailed understanding of these novel regulators of GR signaling may provide more rational approaches to overcoming GC resistance. 
